Benchmark Maintains Buy on NeoGenomics, Lowers Price Target to $18
Portfolio Pulse from jenniferd'souza@benzinga.com
Benchmark analyst Bruce Jackson maintains a Buy rating on NeoGenomics (NASDAQ:NEO) but lowers the price target from $20 to $18.
August 09, 2023 | 4:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Benchmark analyst maintains a Buy rating on NeoGenomics but lowers the price target from $20 to $18.
The news is directly about NeoGenomics. While the Buy rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100